NCT02977494View on ClinicalTrials.gov

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab

Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38

DRUG

Bortezomib

DRUG

Dexamethasone

Trial Locations (10)

Unknown

Charité Universitätsmedizin BerlinCampus Benjamin Franklin, Berlin

Vivantes Klinikum Neukölln, Berlin

Klinikum Chemnitz GmbH, Chemnitz

Katholische Karl-Leisner Klinikum Goch, Goch

Asklepios Klinik Altona, Hamburg

University Hospital Hamburg Eppendorf, Hamburg

Universitätsklinikum Heidelberg, Heidelberg

Univerisity Hospital Muenster, Münster

University Hospital, Tübingen

Alexandra Hopsital, Athens

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT02977494 - Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment | Biotech Hunter | Biotech Hunter